Skip to main content
. 2024 Oct 8;25(6):987–996. doi: 10.1007/s40257-024-00885-w

Fig. 3.

Fig. 3

Best percentage change from baseline in the sum of target lesions per RECIST v1.1 by BICRa. BICR blinded independent central review, RECIST v1.1 Response Evaluation Criteria in Solid Tumors, version 1.1. aIncludes all patients with at least 1 postbaseline assessment